搜索结果：Translational oncology

Thanks to the rapidly evolving integration of LLMs into decision-support tools, a significant transformation is happening across large-scale systems. Like other medical fields, the use of LLMs such as GPT-4 is gaining increasing interest in radiation oncology as well. An attempt to assess GPT-4's performance in radiation oncology was made via a dedicated 100-question examination on the highly specialized topic of radiation oncology physics, revealing GPT-4's superiority over other LLMs. GPT-4's performance on a broader field of clinical radiation oncology is further benchmarked by the ACR Radiation Oncology In-Training (TXIT) exam where GPT-4 achieved a high accuracy of 74.57%. Its performance on re-labelling structure names in accordance with the AAPM TG-263 report has also been benchmarked, achieving above 96% accuracies. Such studies shed light on the potential of LLMs in radiation oncology. As interest in the potential and constraints of LLMs in general healthcare applications continues to rise5, the capabilities and limitations of LLMs in radiation oncology decision support have not yet been fully explored.

Traditional health authority approval for oncology drugs is based on a clinical benefit endpoint, or a valid surrogate. In 1992 the FDA created the Accelerated Approval pathway to allow for earlier approval of therapies in serious conditions with an unmet medical need. This is accomplished typically by granting accelerated approval based on a surrogate endpoint that can be measured earlier than a traditional approval endpoint. Minimal residual disease (MRD) is a sensitive measure of residual cancer cells in hematology oncology after treatment, and is increasingly considered as a secondary or exploratory endpoint due to its prognostic potential for traditional clinical trial endpoints such as progression-free survival (PFS) and overall survival (OS). This work aims to evaluate MRD's surrogacy potential across several hematologic cancer indications while keeping the focus on follicular lymphoma (FL), using data from published studies. We examine individual-level and trial-level correlations extracted from previously published studies to elucidate the potential role of MRD in accelerating the drug approval process in hematology oncology trials.

Accurate trend forecasting in healthcare time series is essential for planning and resource allocation. This paper proposes a Bayesian framework for predicting oncology demand trends, modeling weekly appointments as a Poisson process with a Gamma prior to the demand rate. To enhance adaptability and capture persistent directional patterns, we incorporate a residual-based boosting mechanism grounded in a Gamma-Log-Normal conjugate structure. This boosting approach allows the model to track both short- and long-term trend shifts while maintaining the analytical tractability of conjugate Bayesian updating. The methodology was evaluated on real oncology service data from Cariri, Ceara, Brazil, and compared against established baselines, including linear regression, ARIMA, naive forecasting, LSTM neural networks, and XGBoost. Results showed that the proposed model outperforms competing methods in trend detection accuracy, with gains in terms of percentage of correct direction of 38.25% in relation to the second best approach in some cases.

Introduction. Clinical and Translational Science Award (CTSA) programs must document their scholars' research impact, but assembling each scholar's record by hand takes staff an estimated 15 hours and does not scale to a full cohort. An artificial intelligence (AI) agent could serve as a tool to gather scholar data across platforms and disciplines. Methods. We built a human-in-the-loop AI agent that assembles a dossier of sourced evidence for each scholar and drafts one-sentence Translational Science Benefits Model (TSBM) impact summaries for staff review. We evaluated it in the impact-reporting workflow of one CTSA hub across 10 career-development (KL2/K12) scholars. Two evaluation staff independently coded all 507 findings as accept, edit, or reject; the primary measure was the unanimous usable rate, defined as the share both accepted or edited. Results. Both reviewers accepted or edited 81.7% of the agent's findings. Reviewers each spent a median of 14 minutes per scholar, replacing an estimated 15 hours of manual assembly. Inter-rater agreement was moderate (Cohen's kappa 0.43 on the usable-versus-reject decision). A profile discovery study found the agent's recall close to hum

Precision oncology requires multifunctional platforms capable of integrating accurate tumor diagnosis, localized therapeutic delivery, immune modulation, and real-time monitoring of treatment response. Gelatin methacryloyl (GelMA) hydrogels have emerged as versatile biomaterials for biomedical engineering because of their biocompatibility, extracellular matrix-like structure, tunable mechanical properties, photocrosslinkability, and capacity to incorporate therapeutic agents, imaging probes, and functional nanomaterials. In parallel, manganese-based materials have gained increasing attention as promising alternatives to gadolinium-based magnetic resonance imaging contrast agents and as therapeutic components capable of modulating the tumor microenvironment. Manganese ions and manganese-based nanomaterials can enhance T1-weighted MRI contrast, generate reactive oxygen species, relieve tumor hypoxia, deplete glutathione, promote immunogenic cell death, and activate the cyclic GMP-AMP synthase-Stimulator of Interferon Genes pathway. The integration of manganese-based systems with GelMA hydrogels offers a promising strategy for developing localized, stimuli-responsive, and MRI-guided i

In oncology, access to patient-level data is often restricted. Synthetic data provides an alternative for analyzing treatment effectiveness, but existing methods for synthetic data generation fail to preserve the causal relationships between covariates, treatments, and outcomes, thereby leading to biased estimates of treatment effects. Here, we introduce OncoSynth, a generative, causally-aware machine learning framework designed to produce synthetic cohorts that enable accurate estimation of population- and patient-level treatment effects. OncoSynth uses a diffusion-based sequential approach to model how covariates influence treatment assignment and how treatment affects survival. We evaluate OncoSynth using large lung (N = 37,128) and breast cancer (N = 17,046) cohorts. Our results show that OncoSynth generates high-fidelity synthetic patient cohorts that preserve real-world patient, treatment, and outcome distributions. Notably, OncoSynth improves treatment effect estimation over existing approaches, by reducing population-level treatment effect error by up to 66%, and patient-level treatment effect error by up to 58%. Thereby, OncoSynth supports reliable evidence generation for

In the past year, there has been a growing trend in applying Large Language Models (LLMs) to the field of medicine, particularly with the advent of advanced language models such as ChatGPT developed by OpenAI. However, there is limited research on LLMs specifically addressing oncology-related queries. The primary aim of this research was to develop a specialized language model that demonstrates improved accuracy in providing advice related to oncology. We performed an extensive data collection of online question-answer interactions centered around oncology, sourced from reputable doctor-patient platforms. Following data cleaning and anonymization, a dataset comprising over 180K+ oncology-related conversations was established. The conversations were categorized and meticulously reviewed by field specialists and clinicians to ensure precision. Employing the LLaMA model and other selected open-source datasets, we conducted iterative fine-tuning to enhance the model's proficiency in basic medical conversation and specialized oncology knowledge. We observed a substantial enhancement in the model's understanding of genuine patient inquiries and its reliability in offering oncology-relate

Mathematical oncology is an interdisciplinary research field where the mathematical sciences meet cancer research. Being situated at the intersection of these two fields makes mathematical oncology highly dynamic, as practicing researchers are incentivised to quickly adapt to both technical and medical research advances. Determining the scope of mathematical oncology is therefore not straightforward; however, it is important for purposes related to funding allocation, education, scientific communication, and community organisation. To address this issue, we here conduct a bibliometric analysis of mathematical oncology. We compare our results to the broader field of mathematical biology, and position our findings within theoretical science of science frameworks. Based on article metadata and citation flows, our results provide evidence that mathematical oncology has undergone a significant evolution since the 1960s marked by increased interactions with other disciplines, geographical expansion, larger research teams, and greater diversity in studied topics. The latter finding contributes to the greater discussion on which models different research communities consider to be valuable

Background: The radiation oncology clinical practice involves many steps relying on the dynamic interplay of abundant text data. Large language models have displayed remarkable capabilities in processing complex text information. But their direct applications in specific fields like radiation oncology remain underexplored. Purpose: This study aims to investigate whether fine-tuning LLMs with domain knowledge can improve the performance on Task (1) treatment regimen generation, Task (2) treatment modality selection (photon, proton, electron, or brachytherapy), and Task (3) ICD-10 code prediction in radiation oncology. Methods: Data for 15,724 patient cases were extracted. Cases where patients had a single diagnostic record, and a clearly identifiable primary treatment plan were selected for preprocessing and manual annotation to have 7,903 cases of the patient diagnosis, treatment plan, treatment modality, and ICD-10 code. Each case was used to construct a pair consisting of patient diagnostics details and an answer (treatment regimen, treatment modality, or ICD-10 code respectively) for the supervised fine-tuning of these three tasks. Open source LLaMA2-7B and Mistral-7B models wer

Clinical oncology generates vast, unstructured data that often contain inconsistencies, missing information, and ambiguities, making it difficult to extract reliable insights for data-driven decision-making. General-purpose large language models (LLMs) struggle with these challenges due to their lack of domain-specific reasoning, including specialized clinical terminology, context-dependent interpretations, and multi-modal data integration. We address these issues with an oncology-specialized, efficient, and adaptable NLP framework that combines instruction tuning, retrieval-augmented generation (RAG), and graph-based knowledge integration. Our lightweight models prove effective at oncology-specific tasks, such as named entity recognition (e.g., identifying cancer diagnoses), entity linking (e.g., linking entities to standardized ontologies), TNM staging, document classification (e.g., cancer subtype classification from pathology reports), and treatment response prediction. Our framework emphasizes adaptability and resource efficiency. We include minimal German instructions, collected at the University Hospital Zurich (USZ), to test whether small amounts of non-English language dat

Heterogeneous treatment effect estimation is critical in oncology, particularly in multi-arm trials with overlapping therapeutic components and long-term survivors. These shared mechanisms pose a central challenge to identifying causal effects in precision medicine. We propose a novel covariate-dependent nonparametric Bayesian multi-treatment cure survival model that jointly accounts for common structures among treatments and cure fractions. Through latent link functions, our model leverages sharing among treatments through a flexible modeling approach, enabling individualized survival inference. We adopt a Bayesian route for inference and implement an efficient MCMC algorithm for approximating the posterior. Simulation studies demonstrate the method's robustness and superiority in various specification scenarios. Finally, application to the AALL0434 trial reveals clinically meaningful differences in survival across methotrexate-based regimens and their associations with different covariates, underscoring its practical utility for learning treatment effects in real-world pediatric oncology data.

Cancer remains a leading cause of death worldwide, necessitating personalized treatment approaches to improve outcomes. Theranostics, combining molecular-level imaging with targeted therapy, offers potential for precision oncology but requires optimized, patient-specific care plans. This paper investigates state-of-the-art data-driven decision support applications with a reinforcement learning focus in precision oncology. We review current applications, training environments, state-space representation, performance evaluation criteria, and measurement of risk and reward, highlighting key challenges. We propose a framework integrating data-driven modeling with reinforcement learning-based decision support to optimize radiopharmaceutical therapy dosing, addressing identified challenges and setting directions for future research. The framework leverages Neural Ordinary Differential Equations and Physics-Informed Neural Networks to enhance Physiologically Based Pharmacokinetic models while applying reinforcement learning algorithms to iteratively refine treatment policies based on patient-specific data.

The effectiveness of personalized oncology treatments ultimately depends on whether outcomes can be causally attributed to the treatment. Advances in precision oncology have improved molecular profiling of individuals, and tailored therapies have led to more effective treatments for select patient groups. However, treatment responses still vary among individuals. As cancer is a heterogeneous and dynamic disease with varying treatment outcomes across different molecular types and resistance mechanisms, it requires customized approaches to identify cause-and-effect relationships. N-of-1 trials, or single-subject clinical trials, are designed to evaluate individual treatment effects. Several works have described different causal frameworks to identify treatment effects in N-of-1 trials, yet whether these approaches can be extended to single-cancer patient settings remains unclear. To explore this possibility, a longitudinal dataset from a single metastatic cancer patient with adaptively chosen treatments was considered. The dataset consisted of a detailed treatment plan as well as biomarker and lesion measurements recorded over time. After data processing, a treatment period with suff

Unstructured notes within the electronic health record (EHR) contain rich clinical information vital for cancer treatment decision making and research, yet reliably extracting structured oncology data remains challenging due to extensive variability, specialized terminology, and inconsistent document formats. Manual abstraction, although accurate, is prohibitively costly and unscalable. Existing automated approaches typically address narrow scenarios - either using synthetic datasets, restricting focus to document-level extraction, or isolating specific clinical variables (e.g., staging, biomarkers, histology) - and do not adequately handle patient-level synthesis across the large number of clinical documents containing contradictory information. In this study, we propose an agentic framework that systematically decomposes complex oncology data extraction into modular, adaptive tasks. Specifically, we use large language models (LLMs) as reasoning agents, equipped with context-sensitive retrieval and iterative synthesis capabilities, to exhaustively and comprehensively extract structured clinical variables from real-world oncology notes. Evaluated on a large-scale dataset of over 40

Cancer evolves continuously over time through a complex interplay of genetic, epigenetic, microenvironmental, and phenotypic changes. This dynamic behavior drives uncontrolled cell growth, metastasis, immune evasion, and therapy resistance, posing challenges for effective monitoring and treatment. However, today's data-driven research in oncology has primarily focused on cross-sectional analysis using data from a single modality, limiting the ability to fully characterize and interpret the disease's dynamic heterogeneity. Advances in multiscale data collection and computational methods now enable the discovery of longitudinal multimodal biomarkers for precision oncology. Longitudinal data reveal patterns of disease progression and treatment response that are not evident from single-timepoint data, enabling timely abnormality detection and dynamic treatment adaptation. Multimodal data integration offers complementary information from diverse sources for more precise risk assessment and targeting of cancer therapy. In this review, we survey methods of longitudinal and multimodal modeling, highlighting their synergy in providing multifaceted insights for personalized care tailored to

Background: Lung cancer ranks as the leading cause of cancer-related mortality worldwide. The complexity of tumor delineation, crucial for radiation therapy, requires expertise often unavailable in resource-limited settings. Artificial Intelligence(AI), particularly with advancements in deep learning (DL) and natural language processing (NLP), offers potential solutions yet is challenged by high false positive rates. Purpose: The Oncology Contouring Copilot (OCC) system is developed to leverage oncologist expertise for precise tumor contouring using textual descriptions, aiming to increase the efficiency of oncological workflows by combining the strengths of AI with human oversight. Methods: Our OCC system initially identifies nodule candidates from CT scans. Employing Language Vision Models (LVMs) like GPT-4V, OCC then effectively reduces false positives with clinical descriptive texts, merging textual and visual data to automate tumor delineation, designed to elevate the quality of oncology care by incorporating knowledge from experienced domain experts. Results: Deployments of the OCC system resulted in a significant reduction in the false discovery rate by 35.0%, a 72.4% decrea

Randomized discontinuation design (RDD) is an enrichment strategy commonly used to address limitations of traditional placebo-controlled trials, particularly the ethical concern of prolonged placebo exposure. RDD consists of two phases: an initial open-label phase in which all eligible patients receive the investigational medicinal product (IMP), followed by a double-blind phase in which responders are randomized to continue with the IMP or switch to placebo. This design tests whether the IMP provides benefit beyond the placebo effect. The estimand framework introduced in ICH E9(R1) strengthens the dialogue among clinical research stakeholders by clarifying trial objectives and aligning them with appropriate statistical analyses. However, its application in oncology trials using RDD remains unclear. This manuscript uses the phase III JAVELIN Gastric 100 trial and the phase II trial of sorafenib (BAY 43-9006) as case studies to propose an estimand framework tailored for oncology trials employing RDD in phase III and phase II settings, respectively. We highlight some similarities and differences between RDDs and traditional randomized controlled trials in the context of ICH E9(R1). T

Multimodal Large Language Models (LLMs) hold promise for biomedical reasoning, but current benchmarks fail to capture the complexity of real-world clinical workflows. Existing evaluations primarily assess unimodal, decontextualized question-answering, overlooking multi-agent decision-making environments such as Molecular Tumor Boards (MTBs). MTBs bring together diverse experts in oncology, where diagnostic and prognostic tasks require integrating heterogeneous data and evolving insights over time. Current benchmarks lack this longitudinal and multimodal complexity. We introduce MTBBench, an agentic benchmark simulating MTB-style decision-making through clinically challenging, multimodal, and longitudinal oncology questions. Ground truth annotations are validated by clinicians via a co-developed app, ensuring clinical relevance. We benchmark multiple open and closed-source LLMs and show that, even at scale, they lack reliability -- frequently hallucinating, struggling with reasoning from time-resolved data, and failing to reconcile conflicting evidence or different modalities. To address these limitations, MTBBench goes beyond benchmarking by providing an agentic framework with foun

Purpose To evaluate the reasoning capabilities of large language models (LLMs) in performing root cause analysis (RCA) of radiation oncology incidents using narrative reports from the Radiation Oncology Incident Learning System (RO-ILS), and to assess their potential utility in supporting patient safety efforts. Methods and Materials Four LLMs, Gemini 2.5 Pro, GPT-4o, o3, and Grok 3, were prompted with the 'Background and Incident Overview' sections of 19 public RO-ILS cases. Using a standardized prompt based on AAPM RCA guidelines, each model was instructed to identify root causes, lessons learned, and suggested actions. Outputs were assessed using semantic similarity metrics (cosine similarity via Sentence Transformers), semi-subjective evaluations (precision, recall, F1-score, accuracy, hallucination rate, and four performance criteria: relevance, comprehensiveness, justification, and solution quality), and subjective expert ratings (reasoning quality and overall performance) from five board-certified medical physicists. Results LLMs showed promising performance. GPT-4o had the highest cosine similarity (0.831), while Gemini 2.5 Pro had the highest recall (0.799) and accuracy (0

Multimodal clinical reasoning in the field of gastrointestinal (GI) oncology necessitates the integrated interpretation of endoscopic imagery, radiological data, and biochemical markers. Despite the evident potential exhibited by Multimodal Large Language Models (MLLMs), they frequently encounter challenges such as context dilution and hallucination when confronted with intricate, heterogeneous medical histories. In order to address these limitations, a hierarchical Multi-Agent Framework is proposed, which emulates the collaborative workflow of a human Multidisciplinary Team (MDT). The system attained a composite expert evaluation score of 4.60/5.00, thereby demonstrating a substantial improvement over the monolithic baseline. It is noteworthy that the agent-based architecture yielded the most substantial enhancements in reasoning logic and medical accuracy. The findings indicate that mimetic, agent-based collaboration provides a scalable, interpretable, and clinically robust paradigm for automated decision support in oncology.